Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.
Conclusions: The combination of 2 or 3 comorbidities significantly increases the incidence of symptomatic cancer treatment-related cardiotoxicity. Patients with bca experiencing cancer treatment-related cardiotoxicity who have a history of diabetes, dyslipidemia, and obesity might require more proactive strategies for prevention, detection, and treatment of cardiotoxicity while receiving trastuzumab-based treatment.
PMID: 31285674 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Clinical Trials | Diabetes | Eating Disorders & Weight Management | Endocrinology | Heart | HER2 | Herceptin | Obesity | Study